Amphista is leveraging its first-in-class targeted protein degradation technology to develop an internal pipeline of cancer therapeutics and is open to discussing partnerships to access and co-develop these assets. The technology leverages the body’s innate degradation systems to remove disease-causing proteins.
First-in-class protein
degrading technologies
Amphista is also seeking strategic partnerships with industry leaders to leverage its proprietary technology platform to co-develop assets across all therapy areas.
